Galvani_Bioelectronics

Galvani Bioelectronics

Galvani Bioelectronics

Add article description


Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.

Quick Facts Company type, Industry ...

History

It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]

Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.

In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]


References

  1. "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
  2. "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
  3. Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
  4. "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
  5. Kollewe, Julia (28 August 2017). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 3 August 2018.
  6. "Galvani Bioelectronics". FierceBiotech. Retrieved 13 July 2020.
  7. "Verily Life Sciences". verily.com. Retrieved 15 February 2017.



Share this article:

This article uses material from the Wikipedia article Galvani_Bioelectronics, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.